Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology.
暂无分享,去创建一个
L. Dagna | R. Caporali | S. Kaleci | C. Montecucco | S. Monti | L. Quartuccio | S. De Vita | M. Govoni | G. Emmi | B. Frediani | M. Rossini | F. Cantini | C. Nannini | C. Salvarani | M. Felicetti | R. Padoan | G. Cassone | A. Manfredi | M. Sebastiani | C. Dejaco | A. Berti | S. Bettio | A. Giollo | A. Cariddi | F. Muratore | E. Conticini | L. Argolini | R. Izzo | G. Dallagiacoma
[1] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis , 2022, Annals of the Rheumatic Diseases.
[2] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis , 2022, Annals of the Rheumatic Diseases.
[3] B. Collins,et al. Diagnosis and Management of Fibrotic Interstitial Lung Diseases. , 2021, Clinics in chest medicine.
[4] E. Bargagli,et al. Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association , 2021, Journal of clinical medicine.
[5] F. Ferro,et al. One year in review 2021: systemic vasculitis. , 2021, Clinical and experimental rheumatology.
[6] L. Richeldi,et al. An updated safety review of the drug treatments for idiopathic pulmonary fibrosis , 2021, Expert opinion on drug safety.
[7] M. Wislowska,et al. Subphenotypes of ANCA-associated vasculitis identified by latent class analysis. , 2020, Clinical and Experimental Rheumatology.
[8] N. Sverzellati,et al. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. , 2020, Clinical and experimental rheumatology.
[9] Kevin McCarthy,et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.
[10] L. Corral-Gudino,et al. The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey , 2019, Rheumatology International.
[11] Augustine S. Lee,et al. Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases , 2019, Mayo Clinic proceedings.
[12] Jong Sun Park,et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.
[13] A. Ishizu,et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis , 2018, Nature Reviews Rheumatology.
[14] D. Lynch,et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. , 2017, The Lancet. Respiratory medicine.
[15] K. Mortensen,et al. Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype , 2017, The Journal of Rheumatology.
[16] C. Kallenberg,et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis , 2017 .
[17] M. Alba,et al. Interstital lung disease in ANCA vasculitis. , 2017, Autoimmunity reviews.
[18] Julie K. Watson,et al. Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development , 2017, JCI insight.
[19] D. Cornec,et al. ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients , 2016, Nature Reviews Rheumatology.
[20] Rohit Sharma. Revised International Chapel Hill Consensus Conference nomenclature of vasculitides , 2016, Radiopaedia.org.
[21] N. Inui,et al. Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias , 2016, Lung.
[22] D. Lynch,et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features , 2015, European Respiratory Journal.
[23] Katherine Spinks,et al. The diagnosis and management of interstitial lung diseases , 2015, BMJ : British Medical Journal.
[24] K. Nitta,et al. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] B. Chowdhury,et al. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. , 2015, The New England journal of medicine.
[26] H. Yamanaka,et al. Interstitial Lung Disease with ANCA-associated Vasculitis , 2015, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.
[27] P. Grenier,et al. Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis , 2014, Medicine.
[28] C. Kallenberg. Key advances in the clinical approach to ANCA-associated vasculitis , 2014, Nature Reviews Rheumatology.
[29] Shandra L. Protzko,et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.
[30] E. Miyazaki,et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. , 2013, Respiratory medicine.
[31] Yichun Hu,et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. , 2012, Arthritis and rheumatism.
[32] Sandrine Katsahian,et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis , 2012, Annals of the rheumatic diseases.
[33] T. Colby,et al. Clinical Significance of Serum Autoantibodies in Idiopathic Interstitial Pneumonia , 2012, Journal of Korean medical science.
[34] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.
[35] Kazuo Suzuki,et al. A Comparison of the Clinical Features of ANCA-Positive and ANCA-Negative Idiopathic Pulmonary Fibrosis Patients , 2008, Respiration.
[36] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.
[37] V. Cottin,et al. ANCA-associated lung fibrosis: analysis of 17 patients. , 2008, Respiratory medicine.
[38] Min Chen,et al. Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Older Patients , 2008, Medicine.
[39] D. Scott,et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.
[40] D. Lynch,et al. Rheumatoid arthritis-related lung diseases: CT findings. , 2004, Radiology.
[41] B. Bonnotte,et al. Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. , 2019, Journal of autoimmunity.
[42] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.